Abstract
Background: Anemia during the first 12 week of therapy is the most common side effect of pegylated interferon (PegIFN)/ribavirin (RBV) and telaprevir (TVR) in HCV genotype 1 patients with advanced fibrosis or cirrhosis (F3–F4). Inosine triphosphatase (ITPA) genetic variants are associated with RBV-induced anemia and dose reduction but their role as predictors of anemia during TVR therapy is unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
